DNA methylation and non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 13, Issue 8, 2010, Pages 821-826

  Zhang, Youwei ^a   Chen, Longbang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Biomarker; Lung neoplasms; Methylation; Tumor suppressor gene

Indexed keywords

CANCER THERAPY; DNA METHYLATION; EARLY DIAGNOSIS; LUNG NON SMALL CELL CANCER; PROGNOSIS; RISK ASSESSMENT; SHORT SURVEY;

CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; EPIGENOMICS; HUMANS; LUNG NEOPLASMS;

EID: 78049403944     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2010.08.14     Document Type: Short Survey

References (54)

1. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cell Mol Life Sci, 2009, 66(4): 596-612.
2. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol, 2004, 22(22): 4632-4642.
3. Esteller M. Epigenetics in cancer. N Engl J Med, 2008, 358(11): 1148-1159.
4. Ikegami K, Ohgane J, Tanaka S, et al. Interplay between DNA methylation, histone modification and chromatin remodeling in stem cells and during development. Int J Dev Biol, 2009, 53(2-3): 203-214.
5. Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet, 1999, 21(1): 103-107.
6. Rui W, You-Wei Z, Long-Bang C. Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-email cell lung carcinoma. Lung Cancer, 2009, doi:10.1016/j.lungcan.2009.10.009.
7. Yu J, Bulk E, Ji P, et al. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res, 2010, 16(8): 2275-2283.
8. Choi JE, Kim DS, Kim EJ, et al. Aberrant methylation of ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet, 2008, 187(2): 80-84.
9. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer, 2008, 7: 81.
10. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther, 2001, 1(1): 61-67.
11. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res, 2006, 12(24): 7329-7338. (Pubitemid 46095405)
12. Toyooka S, Tokumo M, Shigematsu H, et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res, 2006, 66(3): 1371-1375.
13. Feng Q, Hawes SE, Stern JE, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev, 2008, 17(3): 645-654. (Pubitemid 351469215)
14. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. Mol Cancer, 2007, 6: 70.
15. Anglim PP, Galler JS, Koss MN, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer, 2008, 7: 62.
16. Ehrich M, Field JK, Liloglou T, et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res, 2006, 66(22): 10911-10918.
17. Fukasawa M, Kimura M, Morita S, et al. Microarray analysis of promoter methylation in lung cancers. J Hum Genet, 2006, 51(4): 368-374.
18. Dai Z, Lakshmanan RR, Zhu WG, et al. Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasma, 2001, 3(4): 314-323.
19. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res, 2006, 16(3): 383-393.
20. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med, 2006, 3: e486.
21. Rauch T, Li H, Wu X, et al. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res, 2006, 66(16): 7939-7947.
22. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA, 2008, 105(1): 252-257.
23. Guan XY, Chen LB. A prospect for early diagnosis of non-small cell lung cancer patients by detection of plasma DNA. Oncol Prog, 2003, 1(4): 187-190.
24. Hsu HS, Chen TP, Hung CH, et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer, 2007, 110(9): 2019-2026.
25. Lin Q, Chen LB, Tang YM, et al. Analysis of promoter hypermethylation of p16 gene in sera from non-small cell lung cancer patients. J Med Postgraduates, 2005, 18(4): 352-354.
26. Lin Q, Chen LB, Tang YM, et al. Analysis of promoter hypermethylation of death assciated protein kinase gene in blood from non-small cell lung cancer patient. J Med Postgraduates, 2005, 18(8): 702-705.
27. Wang Y, Yu Z, Wang T, et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer, 2007, 56(2): 289-294.
28. Zhang YW, Miao YF, Yi J, et al. Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma, 2010, 57(3): 228-233.
29. Zhang Y, Song H, Miao Y, et al. Frequent transcriptional inactivation of Kallikrein 10 gene by CpG island hypermethylation in non-small cell lung cancer. Cancer Sci, 2010, 101(4): 934-940.
30. INK4A hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res, 2002, 8(12): 3782-3787.
31. Shivapurkar N, Stastny V, Suzuki M, et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett, 2007, 247(1): 56-71. (Pubitemid 44959413)
32. Belinsky SA, Klinge DM, Dekker JD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res, 2005, 11(18): 6505-6511. (Pubitemid 41338988)
33. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high risk cohort. Cancer Res, 2006, 66(6): 3338-3344.
34. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol, 2004, 22(12): 2363-2370. (Pubitemid 41115393)
35. Schmiemann V, Bocking A, Kazimirek M, et al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res, 2005, 11(21): 7728-7734.
36. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst, 2000, 92(18): 1511-1516.
37. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst, 2001, 93(9): 691-699.
38. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer, 2008, 99(2): 375-382.
39. Lee SM, Lee JY, Choi JE, et al. Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features. Cancer Genet Cytogenet, 2010, 197(1): 39-45.
40. Heller G, Zielinski CC, Zöchbauer-Müller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev, 2010, 29(1): 95-107.
41. Saito K, Kawakami K, Matsumoto I, et al. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res, 2010, 16(8): 2418-2426.
42. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med, 2008, 358(11): 1118-1128.
43. Toyota M, Suzuki H, Yamashita T, et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci, 2009, 100(5): 787-791.
44. Ramírez JL, Salazar MF, Gupta J, et al. Methylation patterns and chemosensitivity in NSCLC. Adv Exp Med Biol 2006, 587: 195-209.
45. Fischer JR, Ohnmacht U, Rieger N, et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer, 2007, 56(1): 115-1123.
46. de Caceres II, Cortes-Sempere M, Moratilla C, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene, 2010, 29(11): 1681-1690.
47. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res, 2005, 11(10): 3604-3608.
48. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res, 2007, 13(8): 2318-2322.
49. Juergens RA, Vendetti P, Coleman B, et al. A phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC): an interim analysis. J Thorac Oncol, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2009, 27(15S): 8055
50. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell, 2008, 132(1): 9-14.
51. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle, 2008, 7(16): 2591-2600.
52. Gallardo B, Navarro A, Viñolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis, 2009, 30(11): 1903-1909.
53. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res, 2007, 67(4): 1424-1429.
54. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA, 2007, 104(40): 15805-15810.